BiondVax Pharmaceuticals (NASDAQ:BVXV) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

BiondVax Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ BVXV opened at $1.82 on Friday. The company has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $3.74. The company has a debt-to-equity ratio of 5.92, a current ratio of 4.28 and a quick ratio of 4.28. BiondVax Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $13.80. The firm has a market cap of $3.40 million, a PE ratio of -0.51 and a beta of 2.47.

BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last released its quarterly earnings results on Monday, April 17th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Institutional Trading of BiondVax Pharmaceuticals

A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. boosted its position in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,423 shares of the company’s stock after buying an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned approximately 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent quarter.

About BiondVax Pharmaceuticals

(Get Rating)

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.